The results of two phase III trials reported at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer have found that enobosarm, a first-in-class, nonsteroidal, oral selective androgen receptor modulator (SARM), led to an increase in lean body mass (LBM) compared with a decline in LBM observed with placebo for patients with non-small cell lung cancer (NSCLC).
The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization funding and accelerating prostate cancer research.
Adding the NK-1 receptor antagonist aprepitant to standard prophylaxis for chemotherapy-induced nausea and vomiting (CINV) yielded significant benefits for the prevention of CINV in children
A treatment intended to control chemotherapy-induced nausea and vomiting (CINV) that combines netupitant and palonosetron (NEPA) in a single capsule resulted in improved complete response rates (from 0 to 120 hours) when compared with oral palonosetron alone, according to research presented at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer.
"AMEN" mnemonic may assist in sustaining hope.
The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel. The drug is marketed as generic docetaxel and under the brand names Taxotere, Docefrez, and Docetaxel Injection.
Receiving counseling from a genetic healthcare provider before genetic testing educates patients and may help reduce unnecessary procedures
The majority of women with breast cancer who undergo the recommended genetic testing for BRCA1/2 mutations and test positive prior to undergoing surgery will change their surgical plan to include a more extensive procedure, a new study reports.
Recent studies have established the link between a gastric ulcer and stomach cancer. A gastric or peptic ulcer is a sore that can develop on the walls of the stomach when the protective lining in our stomach stops working.
Cancer survivors (defined as people with a history of a cancer diagnosis) represent 4.6% of the U.S. population. The number of survivors is projected to increase at least 30% during the next ten years, and will likely reach 18 million people in the U.S.
The American Cancer Society has released new Prostate Cancer Survivorship Care guidelines that outline post treatment clinical follow-up care for the myriad of long-term and late effects.
A new study has shown that the risk of developing melanoma was more closely related to sun exposure in early life than in adulthood in young Caucasian women.
The program is a live, complementary, educational symposium held in conjunction with the 2014 Pan Pacific Lymphoma Conference
Do you know that ovarian cancer continues to be the deadliest of all gynecologic cancers? Do you know there is no test that detects ovarian cancer?
Please join us for our upcoming telephone/web education program, CLL- Current and Emerging Therapies on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.
Despite evidence supporting its efficacy, chemotherapy is not routinely administered to patients with muscle-invasive bladder cancer (MIBC)
A pilot study of an educational and behavioral program conducted by researchers at the New York University College of Nursing has successfully reduced the risk of lymphedema in breast cancer patients who have undergone axillary lymph node dissection or sentinel lymph node biopsy.
Patients with advanced cancer who received early specialized palliative care reported better quality of life and satisfaction, according to results from a randomized trial comparing such services with usual care published in The Lancet.
A new study published today online in CANCER shows that the majority of breast cancer patients did not meet national physical activity guidelines after they were diagnosed
A recent survey conducted by the National Society of Genetic Counselors (NSGC) showed a significant increase in patient calls and requests for testing and referrals from healthcare providers in the year following actress Angelina Jolie's announcement of her BRCA mutation status and subsequent double mastectomy.
Study examines physical and mental health outcomes of treatment.
Doxepin rinse may prove to be a viable option for the relief of pain associated with oral mucositis in patients with head and neck cancers
A 10-year follow-up study of regional melanoma staging strategies found that patients who underwent sentinel-node biopsies had significantly greater disease-free survival rates (DFSRs) compared with patients monitored through nodal observation.
A study of patients with metastatic melanoma found that those who spent more time in hospice care lived almost four months longer than similar patients who had little or no hospice care, and that end-of-life costs dropped for those with more time in hospice.
Phase III trial results presented at the 2014 ASCO Annual Meeting showed that the dosing frequency of zoledronic acid (Zometa) can be reduced by 67% without compromising effectiveness in women with breast cancer and bone metastases, potentially lowering the risk of serious adverse events.
Adjuvant exemestane reduced the relative risk of developing subsequent invasive cancer in hormone-receptor–positive (HR+) premenopausal women by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS)
Researchers are now asking the question of why?
A new study presented at the 2014 ASCO Annual Meeting has found that adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.
When advanced practice palliative care nurses offer a formal program of palliative care to the family caregivers of patients with advanced cancer soon after diagnosis, the caregivers experience better quality of life, less depression, and a lower sense of caregiver burden,
The ASCO clinical practice guideline now recommends treatment with adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer.
